NAMAPA
Latest Content
As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Health care advocates provide a vital service for patients who are managing chronic conditions.
Advertisement
Advertisement
Trending on Drug Topics
1
Hydrogel-Based Platforms for Chronic Wounds Help Address Infection
2
Some Providers Prescribe Unapproved Retatrutide for Weight Loss at Alarming Rate
3
FDA Warns of Kidney Stone, Injury Risk in Use of OTC Weight-Loss Drug Orlistat
4
FDA Approves Lebrikizumab for 8 Week Maintenance of Atopic Dermatitis
5